![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
1. Diisopyramide
2. Disopyramide
3. Disopyramide Monohydrochloride
4. Disopyramide Phosphate (1:1)
5. Disopyramide Phosphate (1:1), (+-)-isomer
6. Disopyramide Phosphate (1:1), (r)-isomer
7. Disopyramide Phosphate (1:1), (s)-isomer
8. Disopyramide, (+-)-isomer
9. Disopyramide, (r)-isomer
10. Disopyramide, (s)-isomer
11. Disopyramide, D-tartrate (1:1), (s)-isomer
12. Disopyramide, L-tartrate (1:1), (r)-isomer
13. Disopyramide, L-tartrate (1:1), (s)-isomer
14. Disopyramide, L-tartrate (1:2), (+-)-isomer
15. Disopyramide, L-tartrate, (s)-isomer
16. Norpace
17. Palpitin
18. Palpitine
19. Rhythmodan
20. Ritmilen
21. Rythmilen
22. Sc 13957
23. Sc-13957
24. Sc13957
1. 22059-60-5
2. Norpace
3. Disopyramide Phosphate Salt
4. Rythmodan
5. Norpace Cr
6. Sc 7031 Phosphate
7. Dirythmin Sa
8. Diso-duriles
9. Disopyramidephosphate
10. Einecs 244-756-1
11. Sc 7031 (phosphate)
12. Nsc-756744
13. Sc-13957
14. Sc-7031 Phosphate
15. Chebi:4658
16. N6bom1935w
17. 22059-60-5 (phosphate)
18. 2-(1-(ammoniocarbonyl)-3-(diisopropylammonio)-1-phenylpropyl)pyridinium Phosphate
19. Disopyramid Phosphate
20. 4-(diisopropylamino)-2-phenyl-2-(pyridin-2-yl)butanamide Phosphate
21. Sr-01000003039
22. Norpace (tn)
23. Sc 13957
24. Disopyramide (phosphate)
25. Unii-n6bom1935w
26. Schembl41810
27. Mls000028431
28. Spectrum1500261
29. Chembl1201020
30. Hms501i11
31. Dtxsid30944685
32. Disopyramide Phosphate (jan/usp)
33. Hms1920i14
34. Hms2094k15
35. Hms2234b16
36. Hms3259j21
37. Hms3261c04
38. Hms3369l05
39. Hms3652m20
40. Hms3885j07
41. Pharmakon1600-01500261
42. Disopyramide Phosphate [mi]
43. Xaa05960
44. Disopyramide Phosphate [jan]
45. Tox21_500411
46. Ccg-40209
47. Disopyramide Phosphate [usan]
48. Hy-12533a
49. Nsc756744
50. Disopyramide Phosphate [vandf]
51. 4-[di(propan-2-yl)amino]-2-phenyl-2-pyridin-2-ylbutanamide;phosphoric Acid
52. Alpha-(2-diisopropylaminoethyl)-alpha-phenyl-2-pyridineacetamide Phosphate
53. Disopyramide Phosphate [mart.]
54. Disopyramide Phosphate [usp-rs]
55. Disopyramide Phosphate [who-dd]
56. Lp00411
57. Nc00683
58. Nsc 756744
59. (+-)-alpha-(2-(diisopropylamino)ethyl)-alpha-phenyl-2-pyridineacetamide Phosphate (1:1)
60. 2-pyridineacetamide, Alpha-(2-(bis(1-methylethyl)amino)ethyl)-alpha-phenyl-, Phosphate
61. 2-pyridineacetamide, Alpha-(2-(bis(1-methylethyl)amino)ethyl)-alpha-phenyl-, Phosphate (1:1)
62. 2-pyridineacetamide, Alpha-(2-(diisopropylamino)ethyl)-alpha-phenyl-, Phosphate
63. Alpha-(2-(diisopropylamino)ethyl)-alpha-phenyl-2-pyridineacetamide Phosphate (1:1)
64. Ncgc00093836-01
65. Ncgc00093836-02
66. Ncgc00093836-03
67. Ncgc00093836-04
68. Ncgc00261096-01
69. 2-pyridineacetamide, Alpha-(2-(bis(1-methylethyl)amino)ethyl)-alpha-phenyl-, (+-)-, Phosphate (1:1)
70. Smr000058438
71. Db-045779
72. Disopyramide Phosphate [orange Book]
73. Disopyramide Phosphate [ep Monograph]
74. Disopyramide Phosphate [usan:usp:ban:jan]
75. Eu-0100411
76. Ft-0630479
77. S4143
78. Sw196836-3
79. Sw196836-4
80. Disopyramide Phosphate [usp Monograph]
81. C07740
82. D 6035
83. D00637
84. Sr-01000003039-2
85. Sr-01000003039-6
86. Q27106430
87. 4-(diisopropylamino)-2-phenyl-2-(2-pyridyl)butanamide
88. (r)-4-(diisopropylamino)-2-phenyl-2-(pyridin-2-yl)butanamide Phosphate
89. 4-[di(propan-2-yl)amino]-2-phenyl-2-pyridin-2-ylbutanamide,phosphoric Acid
90. 4-diisopropylamino-2-phenyl-2-(2-pyridyl)butyramide Phosphate
91. Disopyramide Phosphate, European Pharmacopoeia (ep) Reference Standard
92. Disopyramide Phosphate, United States Pharmacopeia (usp) Reference Standard
93. (+/-)-.alpha.-(2-(diisopropylamino)ethyl)-.alpha.-phenyl-2-pyridineacetamide Phosphate (1:1)
94. 2-pyridineacetamide, .alpha.-(2-(bis(1-methylethyl)amino)ethyl)-.alpha.-phenyl-, (+/-)-, Phosphate (1:1)
Molecular Weight | 437.5 g/mol |
---|---|
Molecular Formula | C21H32N3O5P |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 8 |
Exact Mass | 437.20795813 g/mol |
Monoisotopic Mass | 437.20795813 g/mol |
Topological Polar Surface Area | 137 Ų |
Heavy Atom Count | 30 |
Formal Charge | 0 |
Complexity | 459 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 6 | |
---|---|
Drug Name | Disopyramide phosphate |
PubMed Health | Disopyramide (By mouth) |
Drug Classes | Antiarrhythmic, Group IA |
Drug Label | Disopyramide Phosphate is an antiarrhythmic drug available for oral administration in capsules containing 100 mg or 150 mg of disopyramide base, present as the phosphate. The base content of the phosphate salt is 77.6%. The structural formula of Diso... |
Active Ingredient | Disopyramide phosphate |
Dosage Form | Capsule |
Route | Oral |
Strength | eq 100mg base; eq 150mg base |
Market Status | Prescription |
Company | Watson Labs; Teva |
2 of 6 | |
---|---|
Drug Name | Norpace |
Active Ingredient | Disopyramide phosphate |
Dosage Form | Capsule |
Route | Oral |
Strength | eq 100mg base; eq 150mg base |
Market Status | Prescription |
Company | Gd Searle |
3 of 6 | |
---|---|
Drug Name | Norpace cr |
PubMed Health | Disopyramide (By mouth) |
Drug Classes | Antiarrhythmic, Group IA |
Drug Label | Norpace (disopyramide phosphate) is an antiarrhythmic drug available for oral administration in immediate-release and controlled-release capsules containing 100 mg or 150 mg of disopyramide base, present as the phosphate. The base content of the phos... |
Active Ingredient | Disopyramide phosphate |
Dosage Form | Capsule, extended release |
Route | Oral |
Strength | eq 100mg base; eq 150mg base |
Market Status | Prescription |
Company | Gd Searle |
4 of 6 | |
---|---|
Drug Name | Disopyramide phosphate |
PubMed Health | Disopyramide (By mouth) |
Drug Classes | Antiarrhythmic, Group IA |
Drug Label | Disopyramide Phosphate is an antiarrhythmic drug available for oral administration in capsules containing 100 mg or 150 mg of disopyramide base, present as the phosphate. The base content of the phosphate salt is 77.6%. The structural formula of Diso... |
Active Ingredient | Disopyramide phosphate |
Dosage Form | Capsule |
Route | Oral |
Strength | eq 100mg base; eq 150mg base |
Market Status | Prescription |
Company | Watson Labs; Teva |
5 of 6 | |
---|---|
Drug Name | Norpace |
Active Ingredient | Disopyramide phosphate |
Dosage Form | Capsule |
Route | Oral |
Strength | eq 100mg base; eq 150mg base |
Market Status | Prescription |
Company | Gd Searle |
6 of 6 | |
---|---|
Drug Name | Norpace cr |
PubMed Health | Disopyramide (By mouth) |
Drug Classes | Antiarrhythmic, Group IA |
Drug Label | Norpace (disopyramide phosphate) is an antiarrhythmic drug available for oral administration in immediate-release and controlled-release capsules containing 100 mg or 150 mg of disopyramide base, present as the phosphate. The base content of the phos... |
Active Ingredient | Disopyramide phosphate |
Dosage Form | Capsule, extended release |
Route | Oral |
Strength | eq 100mg base; eq 150mg base |
Market Status | Prescription |
Company | Gd Searle |
Anti-Arrhythmia Agents
Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)
Voltage-Gated Sodium Channel Blockers
A class of drugs that inhibit the activation of VOLTAGE-GATED SODIUM CHANNELS. (See all compounds classified as Voltage-Gated Sodium Channel Blockers.)